Time trends and gender distribution antidepressant dispensing prevalence (persons/10 000 population/month) in Australians aged 5–19 years
| % Female July 12 to June 13 | % Female July 15 to June 16 | Monthly ave. July 12 to June 13 | Monthly ave. July 15 to June 16 | Rate of increase per month (95% CI)* | % Change, 2012/2013 to 2015/2016 | |
| 5–14 years | ||||||
| Antidepressants | 38 | 41 | 29.00 | 37.99 | 0.22 (0.13 to 0.3) | 31 |
| SSRIs | 38 | 41 | 23.15 | 32.41 | 0.23 (0.16 to 0.3) | 40 |
| Citalopram | † | † | † | † | ||
| Escitalopram | 49 | 45 | 1.34 | 1.94 | 0.014 (0.0065 to 0.021) | 45 |
| Fluoxetine | 37 | 39 | 12.34 | 19.02 | 0.17 (0.13 to 0.21) | 54 |
| Fluvoxamine | 36 | 43 | 3.54 | 4.82 | 0.029 (0.018 to 0.041) | 36 |
| Paroxetine | † | † | † | † | ||
| Sertraline | 38 | 43 | 5.11 | 6.07 | 0.02 (0.0038 to 0.035) | 19 |
| SNRI | † | † | † | † | ||
| NaSSA | † | † | † | † | ||
| TCA | 35 | 41 | 4.73 | 4.21 | −0.019 (−0.028 to −0.01) | −11 |
| 15–19 years | ||||||
| Antidepressants | 65 | 65 | 192.91 | 250.23 | 1.4 (1 to 1.8) | 30 |
| SSRI | 65 | 65 | 147.63 | 198.60 | 1.3 (1 to 1.5) | 35 |
| Citalopram | 67 | 66 | 9.69 | 8.85 | −0.033 (−0.057 to −0.0093) | −9 |
| Escitalopram | 70 | 68 | 30.49 | 39.62 | 0.21 (0.12 to 0.29) | 30 |
| Fluoxetine | 63 | 63 | 55.68 | 80.35 | 0.66 (0.58 to 0.73) | 44 |
| Fluvoxamine | 56 | 57 | 11.09 | 15.89 | 0.12 (0.097 to 0.14) | 43 |
| Paroxetine | 62 | 66 | 3.69 | 5.59 | 0.049 (0.037 to 0.06) | 51 |
| Sertraline | 66 | 66 | 37.79 | 49.83 | 0.31 (0.24 to 0.38) | 32 |
| SNRI | 70 | 70 | 29.31 | 33.42 | 0.071 (−0.02 to 0.16) | 14 |
| Desvenlafaxine | 70 | 70 | 14.39 | 16.13 | 0.027 (−0.018 to 0.072) | 12 |
| Duloxetine | 68 | 71 | 6.20 | 6.33 | −0.0028 (−0.025 to 0.019) | 2 |
| Venlafaxine | 72 | 70 | 8.65 | 10.99 | 0.05 (0.022 to 0.079) | 27 |
| NaSSA | 52 | 54 | 8.28 | 11.01 | 0.067 (0.04 to 0.095) | 33 |
| Mirtazapine | 51 | 54 | 8.19 | 10.98 | 0.069 (0.042 to 0.096) | 34 |
| TCA | 63 | 65 | 10.14 | 11.28 | 0.021 (−0.0023 to 0.045) | 11 |
| 5–19 years | ||||||
| Antidepressants | 59 | 59 | 84.82 | 108.86 | 0.58 (0.41 to 0.76) | 28 |
| SSRI | 59 | 59 | 65.54 | 87.90 | 0.56 (0.43 to 0.69) | 34 |
| Citalopram | 65 | 64 | 3.80 | 3.35 | −0.016 (−0.026 to −0.0067) | −12 |
| Escitalopram | 69 | 66 | 11.26 | 14.52 | 0.073 (0.042 to 0.1) | 29 |
| Fluoxetine | 55 | 55 | 27.10 | 39.50 | 0.33 (0.28 to 0.37) | 46 |
| Fluvoxamine | 48 | 52 | 6.11 | 8.51 | 0.057 (0.044 to 0.071) | 39 |
| Paroxetine | 61 | 65 | 1.41 | 1.95 | 0.014 (0.0092 to 0.018) | 38 |
| Sertraline | 60 | 62 | 16.24 | 20.68 | 0.11 (0.077 to 0.14) | 27 |
| SNRI | 69 | 69 | 10.57 | 11.84 | 0.02 (−0.013 to 0.053) | 12 |
| Desvenlafaxine | 69 | 69 | 5.08 | 5.69 | 0.0091 (−0.0074 to 0.026) | 12 |
| Duloxetine | 66 | 70 | 2.27 | 2.26 | −0.0026 (−0.01 to 0.0053) | 0 |
| Venlafaxine | 70 | 68 | 3.21 | 3.89 | 0.014 (0.0037 to 0.024) | 21 |
| NaSSA | 56 | 52 | 3.14 | 4.08 | 0.023 (0.013 to 0.033) | 30 |
| Mirtazapine | 51 | 53 | 3.11 | 4.07 | 0.023 (0.013 to 0.033) | 31 |
| TCA | 49 | 55 | 6.57 | 6.57 | −0.0066 (−0.018 to 0.0051) | 0 |
Bolded % change figures indicate significant changes (judged by a 95% CI that does not cross zero).
*Based on regression line to account for monthly fluctuation.
†Data were not shown in medicines/classes where there were <30 persons in 10% sample on that class in at least 1 month examined.
NaSSA, noradrenergic and specific serotonergic antidepressant; SNRI, serotonin–norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant.